Recent Findings from Nyxoah's DREAM Study
Nyxoah SA recently shared pivotal findings related to the treatment of Obstructive Sleep Apnea (OSA) at the International Surgical Sleep Society's 2024 Educational Update. This information revealed remarkable data on the effectiveness of their innovative neuromodulation device, Genio®, showcasing a median reduction of 71.0% in the Apnea-Hypopnea Index (AHI) while patients slept on their backs after 12 months.
Overview of Clinical Progress
The details presented highlighted that an impressive 82.0% of those who underwent polysomnography after one year had an AHI under 15, and 67.4% fell below 10. The results underscore a significant stride towards enhancing the quality of sleep and overall well-being for individuals suffering from this condition.
Insights into Treatment Efficacy
During the session, additional metrics were shared, depicting AHI reductions across different sleep positions. The Genio bilateral stimulation technique not only delivered a noteworthy 71.0% decrease in AHI for those sleeping supine but also maintained a comparable reduction across all sleeping positions, recording a median decrease of 70.8% at the 12-month mark.
Improvements in Patients' Lives
Beyond AHI metrics, secondary outcomes exhibited considerable enhancements in quality-of-life measurements. Patients reported a mean increase of 2.3 points in their Functional Outcomes of Sleep Questionnaire (FOSQ) assessment, along with a reduction of 3.4 points in the Epworth Sleepiness Score from their baseline. Such improvements are promising signs of the device's extensive benefits.
Safety and Response Rates
In the DREAM pivotal study, which measured the effectiveness of the Genio implant, conducted among 115 patients, the safety profile remained consistent with existing neuromodulation therapies. There were 11 serious adverse events (SAEs), leading to an SAE rate of just 8.7%. Among the participants, 73 were classified as AHI responders, achieving a 63.5% ITT AHI responder rate, demonstrating the device's significant positive impact.
Expert Insights
B. Tucker Woodson, MD, emphasized the groundbreaking potential of the findings, stating, "The DREAM study demonstrated efficacy of bilateral hypoglossal nerve stimulation using Genio for the treatment of obstructive sleep apnea. Clinically significant improvements were observed in both primary and secondary endpoints of the study." Nyxoah's CEO, Olivier Taelman, echoed these sentiments by highlighting how Genio not only facilitated meaningful AHI reductions irrespective of patient position but also improved overall life quality for over 80% of participants.
Future Directions for Nyxoah
Nyxoah is on the brink of a major milestone as they progress toward obtaining FDA approval. This marks a critical step in making the Genio device accessible to OSA patients in the U.S. With the growing body of evidence supporting its use, this innovative treatment promises to redefine outcomes for those struggling with sleep-related disorders.
About Nyxoah
Nyxoah is dedicated to transforming sleep health for the extensive population affected by OSA globally. This medical technology company has pioneered alternative treatment methodologies leveraging neuromodulation technology. The Genio® system is a testament to Nyxoah's commitment to improving patient outcomes through innovative solutions.
Frequently Asked Questions
What is the Genio® device?
Genio® is a battery-free hypoglossal neuromodulation device developed by Nyxoah for treating obstructive sleep apnea through innovative surgical techniques.
How effective is the Genio® device in treating OSA?
Clinical data from the DREAM study indicates an AHI reduction of 71.0%, with significant improvements in patients' quality of life measured through standard assessment tools.
What are the next steps for Nyxoah regarding regulatory approval?
Nyxoah is advancing toward FDA approval for the Genio® device, aiming to provide access to this effective treatment for patients in the U.S.
What are some reported benefits of the Genio® treatment?
Patients have shown significant reductions in AHI and improvements in quality-of-life metrics, such as the FOSQ and Epworth Sleepiness Score.
How can patients learn more about Nyxoah's treatments?
Interested individuals can explore additional information by visiting Nyxoah's official website or contacting their investor relations team directly.
